Ramiven: The only CDK4/6i that Delivers Proven and Deepening Protection After a 2-year Treatment Period - Video
Overview
In the video, Dr. Carlos Barrios, director and principal investigator of the Oncology Research Center at Hospital São Lucas and president of the Latin American Cooperative Oncology Group (LACOG) in Porto Alegre, Brazil, explains how Ramiven combined with endocrine therapy may improve outcomes for patients with node-positive, high-risk early breast cancer (EBC).
He further notes that two years of Ramiven combined with endocrine therapy, either an aromatase inhibitor or tamoxifen, provides lasting protection for node-positive, high-risk early breast cancer patients.1,2
With Ramiven plus endocrine therapy, more patients remain free of metastatic disease than with endocrine therapy alone.1
About twice as many patients progressed to incurable metastatic disease on endocrine therapy alone compared with Ramiven plus endocrine therapy. The benefit is consistent in patients with 1–3 positive nodes with high-risk features and in those with 4 or more positive lymph nodes. Ramiven helps keep node-positive, high-risk early breast cancer patients on track, with benefits extending beyond the 2-year treatment period.1
References:
1. Rastogi P, et al. J Clin Oncol. 2024;42(9):987–93. 2. Ribociclib, Summary of Product Characteristics, April 2025. 3. Johnston SRD, et al. J Clin Oncol. 2020;38(34):3987–98. 4. Ramiven India Prescribing Information, Literature revised: 6 July 2023, Version Control No. PA008SPIN05 5. Freedman RA, et al. J Clin Oncol. 2024;42(18):2233–5. 6. Loibl S, etal. Ann Oncol. 2024;35(2):159–82. 7. Curigliano G, et al. Ann Oncol.2023;34(11):970–86.
PP-AL-IN-1805 | 17/11/2025
Eli Lilly and Company (India) Private Limited
For further Information about Lilly and Lilly products please contact us at the below address: Plot 92, Sector 32 Gurgaon, Haryana, 122001, India Ph.: +91-124-4753000/01 | www.lilly.com/in
For adverse events and safety reporting, please reach out to: mailbox_in-gps@lilly.com | For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.
This material (including any link) is intended solely for the use of the recipient(s) and may contain confidential information. Any unauthorized review, use, disclosure, copying, or distribution is strictly prohibited. If you are not the intended recipient, please notify the sender immediately and destroy all copies of the material. The information provided in this section is intended solely for the use of registered medical practitioner. This material is being provided to healthcare professionals only for their guidance and use. Nothing on this website/microsite/material should be construed as giving medical advice or making recommendations regarding any health-related decision or action.
© 2025 Eli Lilly and Company
